RIVENDELL GROUP LLP for GENENTECH
What was lobbied
3 issue areas, each in the filer's own words, with who lobbied on it and where.
Health Issues HCR
Legislation impacting pharmaceutical development, pricing and reimbursement; S. 204/HR 878 Tricket Wendler Right to Try Act; Prescription Drug User Fee Act (PDUFA); Drug pricing under 340B program and drug pricing issues generally; Legislation related to repeal and replace of the Affordable Care Act (H.R. 1628 American Healthcare Act of 2017)
| Lobbyist | Covered position, as disclosed |
|---|---|
| MATTHEW LAWRENCE BERZOK | LD and Chief Counsel, Rep. Bart Stupak; LA, Rep. Peter Deutsch |
| NICK KOLOVOS | LA and Counsel, Rep. Anna Eshoo |
Medicare/Medicaid MMM
Issues related to Medicare and Medicaid coverage and reimbursement; Drug pricing under 340B program and drug pricing issues generally; Legislation related to repeal and replace of the Affordable Care Act (H.R. 1628 American Healthcare Act of 2017)
| Lobbyist | Covered position, as disclosed |
|---|---|
| MATTHEW LAWRENCE BERZOK | LD and Chief Counsel, Rep. Bart Stupak; LA, Rep. Peter Deutsch |
| NICK KOLOVOS | LA and Counsel, Rep. Anna Eshoo |
Medical/Disease Research/Clinical Labs MED
Issues relating to drug pricing; issues relating to right to try
| Lobbyist | Covered position, as disclosed |
|---|---|
| MATTHEW LAWRENCE BERZOK | LA and Chief Counsel, Rep. Bart Stupak; LA Rep. Peter Deutsch |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.